-Reuters
Goldman Sachs Maintains Buy on Karuna Therapeutics, Raises Price Target to $278
Goldman Sachs analyst Corinne Jenkins maintains Karuna Therapeutics (NASDAQ:KRTX) with a Buy and raises the price target from $228 to $278.
Related Posts
Parker Hannifin’s Return On Capital Employed Insights
According to Benzinga Pro, during Q3, Parker Hannifin (NYSE:PH) earned $590.96 million, a 49.44% increase from the preceding…
Google Does An Amazon, Will Let Cops Access Smart Home Video Without A Warrant
Alphabet Inc (NASDAQ: GOOGL) (NASDAQ: GOOG) subsidiary Google will reportedly allow the police to access smart home camera footage without a warrant as long as there’s an emergency.
Sight Sciences’ Cataract Surgery Tech Shows Consistent Lowering Of Eye Pressure, Medication Use
Sight Sciences Inc (NASDAQ: SGHT) published two-year results of the so-called "Romeo" study of the OMNI Surgical System.